Research Hub

A structured pre-clinical research program

Bacosane® is supported by pre-clinical studies investigating neurological activity, stress-related behaviour, antioxidant capacity and safety — in vitro testing, multiple animal models and acute plus subacute oral toxicity evaluations.

5
Documented pre-clinical study areas
4
Behavioural and neurological test models
1
Granted US patent
3
Patent applications or registrations
Study index

Current pre-clinical evidence

Study areaDesignModelDoseKey reported outcome
Anticonvulsant activityIn vivo MES and PTZ modelsAlbino rats and mice50 and 100 mg/kgDose-responsive activity; 67% protection at 50 mg/kg and 84% protection at 100 mg/kg in the PTZ model.
Anxiolytic activity (Actophotometer)Actophotometer methodMale and female Wistar rats50 and 100 mg/kgSignificant reduction in immobility time and dose-dependent anti-anxiety effects.
Anxiolytic activity (Elevated Plus Maze)Elevated Plus Maze testWistar rats (n=6 per group)50 and 100 mg/kgIncreased open-arm entries (up to 49.2%) and time in open arms vs. control.
Antioxidant activityIn vitro DPPH assayLaboratory assay vs BHTConcentration-dependentIC50 150.50 µg/mL (BHT reference 87.25 µg/mL); supports SOD, CAT, GPX, GSR.
Acute oral toxicityIn vivo safety studyAlbino rats5,000 mg/kgNo mortality, apparent toxicity or significant differences (p > 0.05) vs control.
Subacute oral toxicity28-day repeated doseAlbino rats250, 500 and 1,000 mg/kgNo mortality, organ toxicity or significant differences (p > 0.05) in biochemistry or hematology.

This index summarizes preclinical research across validated animal and laboratory models, establishing a rigorous scientific baseline for ongoing human clinical trials.

Explore Research

Detailed scientific dossiers

Download the Bacosane® research dossier

Access the preclinical efficacy, mechanistic, safety and patent documentation for technical review.